الفهرس 
The effect of oral pre-treatment by nicorandil on the outcome of PCI in patients with ACS
ContentOnly 14 pages are availabe for public view
 |  | from | 192 |  |  |
| | | from | 192 | | |
Abstract
Coronary artery disease (CAD) is considered to be the most common disease worldwide and has the highest mortality rate in the western countries. 1 In recent years, percutaneous coronary intervention (PCI) has become the principal means of revascularization in patients with CAD. 2-3 No reflow or slow flow occurs in 3-4% of all percutaneous coronary interventions. The current available approaches to prevent and treat no-reflow include IIBIIIA blockers, adenosine, nitroprusside, and mechanical thrombectomy aspiration devices. Nicorandil is an ATP sensitive potassium channel (KATP) open agent with the effect of nitrate. 4, 5 Intravenous nicorandil before PCI can significantly reduce the incidence of coronary slow flow after postoperative. 6, 7 nicorandil can antagonize ADP induced platelet aggregation, improve microcirculation in ischemic area and decrease no reflow phenomenon. 8 In our study, we have detected the effect of oral pre-treatment by nicorandil on the outcome of PCI in patients with ACS. The aim of the study: Primary was evaluation of post procedural no-reflow and slow flow phenomenon by evaluation TIMI flow and cTFC pre and post PCI and secondary was evaluation of peri-procedure myocardial infarction (MI) and one month major adverse cardiac events MACE